Federal Drug Agency Approved First Generic Competitor to EpiPen
The Federal Drug Agency has approved the first generic competitor to the EpiPen. It's a big deal because Mylan, the maker of EpiPens, holds 90 percent of the market share on Epinephrine auto injectors, ranging anywhere from $300 to $600.
With Teva Pharmaceuticals stepping in, prices could drop even more, something parents say is long overdue.
Teva Pharmaceuticals has not announced its price for the generic but says it should be available in the coming months. Click here on WILX-TV 10 for more information.